COST-EFFECTIVENESS OF EVOLOCUMAB IN ATHEROSCLEROTIC CARDIOVASCULAR DISEASE PATIENTS WITH VARYING RISK PROFILES IN SWEDEN

被引：0
|
作者：
Lindgren, P. [1 ]
Hagstrom, E. [2 ]
van Hout, B. [3 ]
Villa, G. [4 ]
Pemberton-Ross, P. [4 ]
Arellano, J. [5 ]
Sibartie, M. [4 ]
Fonarow, G. C. [6 ]
机构：
[1] Karolinska Inst, Stockholm, Sweden
[2] Uppsala Univ, Uppsala, Sweden
[3] Univ Sheffield, Sheffield, S Yorkshire, England
[4] Amgen Europe GmbH, Rotkreuz, Switzerland
[5] Amgen Inc, Thousand Oaks, CA 91320 USA
[6] Univ Calif Los Angeles, Los Angeles, CA USA
来源：
VALUE IN HEALTH | 2019年 / 22卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCV40
引用
收藏
页码：S548 / S548
页数：1
相关论文
共 50 条
  • [1] Cost-effectiveness of evolocumab in patients with high atherosclerotic cardiovascular risk in Sweden
    Lindgren, P.
    Hagstrom, E.
    Van Hout, B.
    Villa, G.
    Urbich, M.
    Sandelin, R.
    Svensson, M. Eriksson
    Fonarow, G. C.
    EUROPEAN HEART JOURNAL, 2019, 40 : 681 - 681
  • [2] Cost-effectiveness of Evolocumab Therapy for Reducing Cardiovascular Events in Patients With Atherosclerotic Cardiovascular Disease
    Fonarow, Gregg C.
    Keech, Anthony C.
    Pedersen, Terje R.
    Giugliano, Robert P.
    Sever, Peter S.
    Lindgren, Peter
    van Hout, Ben
    Villa, Guillermo
    Qian, Yi
    Somaratne, Ransi
    Sabatine, Marc S.
    JAMA CARDIOLOGY, 2017, 2 (10) : 1069 - 1078
  • [3] Cost-Effectiveness Analysis of Evolocumab in Adult Patients with Atherosclerotic Cardiovascular Disease in Canada
    Gregoire, Jean
    Champsi, Salimah
    Jobin, Manon
    Martinez, Laura
    Urbich, Michael
    Rogoza, Raina M.
    ADVANCES IN THERAPY, 2022, 39 (07) : 3262 - 3279
  • [4] Cost-Effectiveness Analysis of Evolocumab in Adult Patients with Atherosclerotic Cardiovascular Disease in Canada
    Jean Grégoire
    Salimah Champsi
    Manon Jobin
    Laura Martinez
    Michael Urbich
    Raina M. Rogoza
    Advances in Therapy, 2022, 39 : 3262 - 3279
  • [5] Updated Cost-effectiveness Analysis of Evolocumab in Patients With Very High-risk Atherosclerotic Cardiovascular Disease
    Fonarow, Gregg C.
    van Hout, Ben
    Villa, Guillermo
    Arellano, Jorge
    Lindgren, Peter
    JAMA CARDIOLOGY, 2019, 4 (07) : 691 - 695
  • [6] Cost-Effectiveness of Evolocumab in Adult Patients with Atherosclerotic Cardiovascular Disease from Chinese Healthcare Perspective
    Wenwen Xie
    Yinyin Song
    Xiaomei Qin
    Pengfei Jin
    Advances in Therapy, 2023, 40 : 489 - 503
  • [7] Cost-Effectiveness of Evolocumab in Adult Patients with Atherosclerotic Cardiovascular Disease from Chinese Healthcare Perspective
    Xie, Wenwen
    Song, Yinyin
    Qin, Xiaomei
    Jin, Pengfei
    ADVANCES IN THERAPY, 2023, 40 (02) : 489 - 503
  • [8] COST-EFFECTIVENESS OF EVOLOCUMAB IN PATIENTS WITH HIGH CARDIOVASCULAR RISK IN SPAIN
    Villa, G.
    Lothgren, M.
    Kutikova, L.
    Lindgren, P.
    Gandra, S. R.
    Fonarow, G. C.
    Sorio, F.
    Masana, L.
    Bayes-Genis, A.
    van Hout, B.
    VALUE IN HEALTH, 2016, 19 (07) : A651 - A652
  • [9] Cost-effectiveness of Evolocumab in Patients With High Cardiovascular Risk in Spain
    Villa, Guillermo
    Lothgren, Mickael
    Kutikova, Lucie
    Lindgren, Peter
    Gandra, Shravanthi R.
    Fonarow, Gregg C.
    Sorio, Francesc
    Masana, Lluis
    Bayes-Genis, Antoni
    van Hout, Ben
    CLINICAL THERAPEUTICS, 2017, 39 (04) : 771 - 786
  • [10] Cost-effectiveness of Evolocumab in Cardiovascular Disease: A Systematic Review
    Ghadimi, Nashmil
    Daroudi, Rajabali
    Shabaninejad, Hosein
    Goharimehr, Mahshad
    Khodamorzideh, Davoud
    Kaveh, Sara
    CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 2024, 101
12345